Search results for "Cost-Effectiveness Analysis"

showing 10 items of 32 documents

Coauthorship and institutional collaborations on cost-effectiveness analyses: a systematic network analysis

2012

BackgroundCost-Effectiveness Analysis (CEA) has been promoted as an important research methodology for determining the efficiency of healthcare technology and guiding medical decision-making. Our aim was to characterize the collaborative patterns of CEA conducted over the past two decades in Spain.Methods and findingsA systematic analysis was carried out with the information obtained through an updated comprehensive literature review and from reports of health technology assessment agencies. We identified CEAs with outcomes expressed as a time-based summary measure of population health (e.g. quality-adjusted life-years or disability-adjusted life-years), conducted in Spain and published bet…

Knowledge managementNon-Clinical MedicineCost effectivenessScience PolicyEconomicsPolitical ScienceCost-Benefit AnalysisSciencePublic PolicyBibliometricsTechnology assessmentSocial and Behavioral SciencesInvestigacióHealth EconomicsSociologyMedicineCooperative BehaviorHealth Systems StrengtheningMultidisciplinaryHealth economicsHealth Care PolicyCost–benefit analysisbusiness.industryQHealth services researchRHealth technologyCost-effectiveness analysisResearch AssessmentAuthorshipSocial NetworksBibliometricsMedicinebusinessResearch Article
researchProduct

Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-leve…

2019

Background The precise age distribution and calculated stroke risk of screen-detected atrial fibrillation (AF) is not known. Therefore, it is not possible to determine the number needed to screen (NNS) to identify one treatable new AF case (NNS-Rx) (i.e., Class-1 oral anticoagulation [OAC] treatment recommendation) in each age stratum. If the NNS-Rx is known for each age stratum, precise cost-effectiveness and sensitivity simulations can be performed based on the age distribution of the population/region to be screened. Such calculations are required by national authorities and organisations responsible for health system budgets to determine the best age cutoffs for screening programs and d…

MaleHealth ScreeningEconomicsSocial Sciences030204 cardiovascular system & hematologyVascular MedicineScreening programmeElectrocardiography0302 clinical medicineRisk FactorsHealth careAtrial FibrillationMedicine and Health SciencesMass ScreeningPublic and Occupational Health030212 general & internal medicinemedia_commonAged 80 and overRAge FactorsGeneral MedicineMiddle AgedUniversity hospitalPrognosis3. Good healthStrokeBioassays and Physiological AnalysisNeurologyHealthMedicineFemaleTraining programArrhythmiaResearch ArticleAdultCerebrovascular DiseasesCost-Effectiveness AnalysisCardiologyLibrary scienceResearch and Analysis MethodsRisk AssessmentStroke risk03 medical and health sciencesYoung AdultAge DistributionSex FactorsPopulation MetricsPredictive Value of TestsPolitical sciencemedia_common.cataloged_instanceHumansEarly careerEuropean unionIschemic StrokeAgedHealth Care PolicyPopulation Biologybusiness.industryElectrophysiological TechniquesBiology and Life SciencesNumber needed to screenEconomic AnalysisHealth CareAge GroupsPeople and PlaceseHealthPopulation GroupingsCardiac ElectrophysiologybusinessScreening Guidelines
researchProduct

Economic evaluation of a guided and unguided internet-based CBT intervention for major depression: Results from a multicenter, three-armed randomized…

2017

Depression is one of the most common mental disorders and will become one of the leading causes of disability in the world. Internet-based CBT programs for depression have been classified as well established following the American Psychological Association criteria for empirically supported treatments. The aim of this study is to analyze the cost effectiveness at 12-month follow-up of the Internet-based CBT program Smiling is fun with (LITG) and without psychotherapist support (TSG) compared to usual care. The perspective used in our analysis is societal. A sample of 296 depressed patients (mean age of 43.04 years; 76% female; BDI-II mean score = 22.37) from primary care services in four Sp…

MaleSpanish PeopleEconomicsPsychological interventionSocial SciencesSeverity of Illness Indexlaw.invention:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Learning and Memory0302 clinical medicineHispanoamericanosEthnicitiesPsychologyAnálisis de intención de tratarlcsh:Sciencemediana edadancianoDepressionAntidepressantsadulto:Health Care::Health Services Administration::Patient Care Management::Comprehensive Health Care::Primary Health Care [Medical Subject Headings]Humanosadulto joven:Health Care::Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Controlled Clinical Trials as Topic::Randomized Controlled Trials as Topic::Intention to Treat Analysis [Medical Subject Headings]Psicoterapia:Information Science::Information Science::Computing Methodologies::Computer Systems::Computer Communication Networks::Internet [Medical Subject Headings]medicine.medical_specialtyEvidence-based practiceGrupos control03 medical and health sciences:Health Care::Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost-Benefit Analysis [Medical Subject Headings]Drug TherapySeverity of illnessHumans:Persons::Persons::Age Groups::Adult [Medical Subject Headings]psicoterapiaAgedPharmacologyDepressive DisorderDepressive Disorder MajorInternetPrimary Health CareMood Disorderslcsh:RBiology and Life SciencesSonrisa030227 psychiatryHealth CareAnálisis costo-beneficio:Check Tags::Female [Medical Subject Headings]Economic evaluationlcsh:QPopulation GroupingsNeuroscienceGerontologyFinancial ManagementCost effectivenessCost-Benefit Analysishumanosadolescentelcsh:MedicineTrastorno depresivoRandomized controlled triallawDepresiónMedicine and Health Sciences030212 general & internal medicineMultidisciplinaryAdultoPharmaceuticsresultado del tratamientoFemeninoDrugsCost-effectiveness analysisMiddle AgedTelemedicineTreatment OutcomeSociedades científicasFemale:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Communication::Nonverbal Communication::Facial Expression::Smiling [Medical Subject Headings]Estudios de seguimiento:Persons::Persons::Population Groups::Ethnic Groups::Hispanic Americans [Medical Subject Headings]telemedicinaResearch ArticleAdultAdolescent:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Methods::Research Design::Control Groups [Medical Subject Headings]:Psychiatry and Psychology::Behavioral Disciplines and Activities::Psychotherapy [Medical Subject Headings]Cost-Effectiveness AnalysisMEDLINEYoung Adulttrastorno depresivoAtención primaria de saludMental Health and PsychiatryIndirect CostsmedicineLearningíndice de gravedad de la enfermedadPrimary Care:Psychiatry and Psychology::Mental Disorders::Mood Disorders::Depressive Disorder [Medical Subject Headings]:Health Care::Health Care Economics and Organizations::Organizations::Societies::Societies Scientific [Medical Subject Headings]Cognitive Behavioral Therapybusiness.industryCognitive Psychology:Health Care::Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Follow-Up Studies [Medical Subject Headings]Economic AnalysisPsychotherapyPeople and PlacesPhysical therapyCognitive Science:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Behavioral Symptoms::Depression [Medical Subject Headings]businessFinance
researchProduct

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer.

2021

To evaluate the cost-effectiveness of first-line treatments, such as erlotinib, gefitinib, afatinib, dacomitinib, and osimertinib, for patients diagnosed with stage IIIB/IV NSCLC harboring EGFR mutations.A partitioned survival model was developed to estimate quality-adjusted life-year (QALY) and incremental cost-effectiveness ratio (ICER) from the perspective of the Spanish National Health System. Two Bayesian NMAs were performed independently, by using the polynomial fraction method to fit Kaplan-Meier curves for overall survival and progression-free survival. Deterministic and probabilistic sensitivity analyses were performed to evaluate the uncertainty.The ICER was calculated for the fou…

Oncologycongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyLung NeoplasmsCost effectivenessAfatinibCost-Benefit AnalysisAfatinibchemistry.chemical_compoundErlotinib HydrochlorideGefitinibInternal medicineCarcinoma Non-Small-Cell LungmedicineHumansheterocyclic compoundsPharmacology (medical)OsimertinibLung cancerneoplasmsProtein Kinase Inhibitorsbusiness.industryHealth PolicyBayes TheoremGefitinibGeneral MedicineCost-effectiveness analysismedicine.diseaseDacomitinibrespiratory tract diseasesErbB ReceptorschemistryMutationErlotinibbusinessmedicine.drugExpert review of pharmacoeconomicsoutcomes research
researchProduct

Genomic profile of breast cancer: costeffectiveness analysis from the Spanish National Healthcare System perspective.

2014

Background: Costeffectiveness analysis of MammaPrint® (70-gene signature) in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy. Methods: Markov model assuming a cohort of 60-year-old women with breast cancer. Treatment costs and effects were assessed by comparing the 5-year, 10-year and lifetime risk of recurrence using Adjuvant! Online® (online algorithm), 70-gene signature or Oncotype DX® (21-gene assay). Results: 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene assay and online algorithm, with associated quality-adjusted life year gains up to 0.23 …

Oncologymedicine.medical_specialtyCost effectivenessCost effectivenessCàncer de mamaBreast cancerBreast cancerMammaPrintInternal medicinemedicinePharmacology (medical)Online algorithmEspanyaGynecologyPublic healthmedicine.diagnostic_testbusiness.industryHealth PolicyEconomic analysisGeneral MedicineCost-effectiveness analysisGenomicsAnàlisi cost-beneficimedicine.diseaseSalut públicaGenòmicaSpainCohortLife expectancyAnàlisi econòmicabusinessOncotype DX
researchProduct

Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost–effectiveness analysis

2019

Aim: Osimertinib improves progression-free survival in first-line EGFR mutation–positive non-small-cell lung cancer. Materials & methods: A Markov cohort model including costs, utilities and disutilities, was conducted to estimate quality-adjusted life-year (QALY) and incremental cost–effectiveness ratio when treating with osimertinib versus standard first-line tyrosine kinase inhibitors (TKIs). Results: Osimertinib presented higher QALYs (0.61) compared with standard EGFR–TKIs (0.42). Osimertinib costs were €83,258.99, in comparison with €29,209.45 for the standard EGFR–TKIs. An incremental cost–effectiveness ratio of €273,895.36/QALY was obtained for osimertinib. Conclusion: Osimerti…

Oncologymedicine.medical_specialtyLung NeoplasmsCost effectivenessCost-Benefit AnalysisAntineoplastic Agents03 medical and health scienceschemistry.chemical_compoundEgfr tki0302 clinical medicineCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansOsimertinib030212 general & internal medicineLung cancerProtein Kinase Inhibitorshealth care economics and organizationsAcrylamidesAniline Compoundsbusiness.industryHealth PolicyCost-effectiveness analysismedicine.diseaseMarkov ChainsDacomitinibrespiratory tract diseasesErbB ReceptorsFirst line treatmentchemistry030220 oncology & carcinogenesisMutationQuality-Adjusted Life YearsNon small cellbusinessModels EconometricJournal of Comparative Effectiveness Research
researchProduct

Options pour une allocation coût-efficace des ressources

2006

06043; L'analyse coût-efficace de la qualité de l'éducation cherche à identifier la relation entre, d'une part, les moyens et les modes d'organisation scolaire et, d'autre part, les résultats obtenus. C'est cette relation que nous examinons dans ce chapitre, organisé en trois grandes sections. La première fixe le cadre financier général de la politique éducative et étudie la manière dont les problématiques liées à la qualité des services offerts s'y inscrivent. La deuxième s'attache de façon plus spécifique aux facteurs de l'organisation scolaire, en mettant en regard leur impact sur les acquis des élèves et leur coût et en examinant les options possibles pour leur mise en oeuvre et leur co…

Organisation scolaireEducational qualityEducation policyQualité de l'éducation[SHS.EDU]Humanities and Social Sciences/Education[SHS.EDU] Humanities and Social Sciences/EducationPolitique éducativeAnalyse coût-efficacité[ SHS.EDU ] Humanities and Social Sciences/EducationAcquis scolaire[SHS.ECO]Humanities and Social Sciences/Economics and FinanceSchool organizationAllocation des ressources[ SHS.ECO ] Humanities and Social Sciences/Economies and finances[SHS.ECO] Humanities and Social Sciences/Economics and FinanceEducational AttainmentCost-effectiveness Analysis
researchProduct

2019

Background Congenital Toxoplasmosis (CT) can have severe consequences. France, Austria, and Slovenia have prenatal screening programs whereas some other countries are considering universal screening to reduce congenital transmission and severity of infection in children. The efficiency of such programs is debated increasingly as seroprevalence among pregnant women and incidence of congenital toxoplasmosis show a steady decrease. In addition, uncertainty remains regarding the effectiveness of pre- and postnatal treatments. Method To identify cost-effective strategies, prenatal and neonatal screenings were compared using a decision-analytic model based on French guidelines and current knowled…

Pediatricsmedicine.medical_specialtyPregnancyMultidisciplinaryCost effectivenessbusiness.industryIncidence (epidemiology)030231 tropical medicinePrevalenceCost-effectiveness analysismedicine.diseaseToxoplasmosis3. Good health03 medical and health sciences0302 clinical medicineEpidemiologyCohortmedicine030212 general & internal medicinebusinessPLOS ONE
researchProduct

Cost-Effectiveness Analysis: Stress Ulcer Bleeding Prophylaxis with Proton Pump Inhibitors, H2 Receptor Antagonists

2012

Abstract Objectives Proton pump inhibitors (PPIs) and H2-receptor antagonists (H2RAs) present varying pharmacological efficacy in preventing stress ulcer bleeding (SUB) in intensive care units. The literature also reports disparate rates of ventilator-assisted pneumonia (VAP) as side effects of these treatments. We compared the cost-effectiveness of these two prophylactic pharmacological options. Methods We constructed a decision tree with a 60-day time horizon for patients at high risk for developing SUB, receiving either PPIs or H2RAs. For each treatment strategy, patients could be in one of three states of health: SUB, VAP, or no complication. Contemporary, clinically relevant probabilit…

Peptic Ulcermedicine.medical_specialtyMultivariate analysisDatabases FactualCost effectivenessmedicine.drug_classCost-Benefit AnalysisMEDLINEProton-pump inhibitorH2RAIntensive careInternal medicinemedicineHumanscost-effectivenessbusiness.industryHealth PolicyStress ulcerDecision TreesPublic Health Environmental and Occupational HealthProton Pump InhibitorsHealth Care CostsCost-effectiveness analysisLength of StayAnti-Ulcer Agentsmedicine.diseaseUnited StatesSurgerystress ulcer bleedingHistamine H2 AntagonistsMultivariate AnalysisGastrointestinal HemorrhagebusinessComplicationValue in Health
researchProduct

Tools for education : policy analysis

2003

03125http://www-wds.worldbank.org/servlet/WDSContentServer/WDSP/IB/2003/06/06/000094946_03052904033567/Rendered/PDF/multi0page.pdf; This hands-on, interactive guide to evaluating and revamping education policy is designed to help policymakers in low-income countries identify weakness and make the most efficient use of scarce education resources. Education specialist in the developed world will also find this guide to be an invaluable tool for analyzing priorities and arriving at cost-effective solutions. The out-growth of training workshops held at the World Bank, this book and CD-ROM present relevant policy problems and engage the user in a search for effective education-service delivery o…

Politique de l'éducationEducation policy[SHS.EDU]Humanities and Social Sciences/Education[SHS.EDU] Humanities and Social Sciences/EducationEnseignantAnalyse de coûtEvaluation du système éducatifCost analysis[ SHS.ECO ] Humanities and Social Sciences/Economies and financesAnalyse de régressionEquité[SHS.ECO] Humanities and Social Sciences/Economics and FinanceScolarisation des fillesTechnologie de l'éducationCost-effectiveness analysisGender - Gender and Education Health Monitoring and Evaluation Teaching and Learning Curriculum and Instruction Education - Primary Education Health Nutrition and PopulationComparative analysisEconomic analysisOutil statistiqueAnalyse coût-efficacitéEvaluation de l'éducation[ SHS.EDU ] Humanities and Social Sciences/EducationAnalyse économique[SHS.ECO]Humanities and Social Sciences/Economics and FinanceSalaireOrganisation pédagogiqueEducation EvaluationAnalyse comparativeFormation des enseignantsStatistical toolEducational system
researchProduct